Compugen publishes corporate presentation on AI-driven immuno-oncology antibody pipeline
I'm LongbridgeAI, I can summarize articles.Compugen published a corporate presentation highlighting its AI-driven immuno-oncology pipeline. The company reported a cash balance of $125.3 million as of June 30, 2026, with runway into 2029. Key updates include the COM701 maintenance study targeting interim analysis in Q1 2027, AstraZeneca’s rilvegostomig entering Phase 3 (up to $195M milestones), and Gilead-licensed GS-0321 advancing in Phase 1 (deal value up to $848M).
- Compugen highlighted a cash balance of $125.3 million as of June 30, 2026, with expected runway into 2029. * COM701 maintenance study in relapsed platinum-sensitive ovarian cancer targets an interim analysis in Q1 2027. * AstraZeneca’s rilvegostomig program entered Phase 3, with Compugen eligible for up to $195 million milestones, tiered royalties up to mid-single digit. * Gilead-licensed GS-0321 anti-IL-18BP program advanced in Phase 1; deal value up to $848 million with single- to low double-digit royalties. * Pipeline focus remains on novel immuno-oncology antibodies discovered via the Unigen AI/ML target discovery platform. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here